Pathways for bone loss in inflammatory disease

Current Osteoporosis Reports

Volumn 10, Issue 2, 2012, Pages 101-108

  Braun, Tobias ^a   Schett, Georg ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Bone loss; Inflammatory disease; Osteoporosis

Indexed keywords

BORTEZOMIB; COLONY STIMULATING FACTOR 1; CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 34; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNE DISEASE; CELL DIFFERENTIATION; CELL FUNCTION; DRUG MECHANISM; HOMEOSTASIS; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; INFLAMMATORY DISEASE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PATHOPHYSIOLOGY; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

ANIMALS; CYTOKINES; HUMANS; INFLAMMATION; MACROPHAGE COLONY-STIMULATING FACTOR; MODELS, ANIMAL; OSTEOPOROSIS; RANK LIGAND; SIGNAL TRANSDUCTION;

EID: 84865801449     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-012-0104-5     Document Type: Article

References (96)

1. Braun T, Zwerina J. Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis. Arthritis Res Ther. 2011;13 (4):235.
2. Nakashima T, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011; 17 (10):1231-4.
3. Yeo L, et al. Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis. Ann Rheum Dis. 2011;70(11):2022-8.
4. Ellabban AS, et al. Receptor activator of nuclear factor kappa B ligand serum and synovial fluid level. A comparative study between rheumatoid arthritis and osteoarthritis. Rheumatol Int 2011, Feb 17.
5. Boumans MJ, et al. Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis. Ann Rheum Dis. 2012;71(1):108-13.
6. Mabilleau G, et al. Depth and volume of resorption induced by osteoclasts generated in the presence of RANKL, TNF-alpha/IL-1 or LIGHT. Cytokine. 2012;57(2):294-9.
7. Jang E, et al. Deficiency of foxp3 regulatory T cells exacerbates autoimmune arthritis by altering the synovial proportions of CD4 T cells and dendritic cells. Immune Netw. 2011;11(5):299-306.
8. Claro T, et al. Staphylococcus aureus protein A binds to osteoblasts and triggers signals that weaken bone in osteomyelitis. PLoS One. 2011;6(4):e18748.
9. Lee SJ, et al. Bone destruction by receptor activator of nuclear factor kappaB ligand-expressing T cells in chronic gouty arthritis. Arthritis Res Ther. 2011;13(5):R164.
10. Choe JY, Lee GH, Kim SK. Radiographic bone damage in chronic gout is negatively associated with the inflammatory cytokines soluble interleukin 6 receptor and osteoprotegerin. J Rheumatol. 2011;38(3):485-91.
11. Hwang SY, Putney JW. Orai1-mediated calcium entry plays a critical role in osteoclast differentiation and function by regulating activation of the transcription factor NFATc1. FASEB J. 2011.
12. Noh AL, et al. L-type Ca(2+) channel agonist inhibits RANKL-induced osteoclast formation via NFATc1 down-regulation. Life Sci. 2011;89(5-6):159-64.
13. Yamaguchi M, Weitzmann MN, Murata T. Exogenous regucalcin stimulates osteoclastogenesis and suppresses osteoblastogenesis through NF-kappaB activation. Mol Cell Biochem. 2012;359(1-2):193-203.
14. Lee YR, et al. SPA0355, a thiourea analogue, inhibits inflammatory responses and joint destruction in fibroblast-like synoviocytes and mice with collagen-induced arthritis. Br J Pharmacol. 2011;164 (2b):794-806.
15. Soysa NS, et al. Defective nuclear factor-kappaB-inducing kinase in aly/aly mice prevents bone resorption induced by local injection of lipopolysaccharide. J Periodontal Res. 2011;46(2):280-4.
16. Liu S, et al. The large zinc finger protein ZAS3 is a critical modulator of osteoclastogenesis. PLoS One. 2011;6(3):e17161.
17. Mabilleau G, Chappard D, Sabokbar A. Role of the A20-TRAF6 axis in lipopolysaccharide-mediated osteoclastogenesis. J Biol Chem. 2011;286(5):3242-9.
18. Bishop KA, et al. Mouse Rankl expression is regulated in T cells by c-Fos through a cluster of distal regulatory enhancers designated the T cell control region. J Biol Chem. 2011;286(23):20880-91.
19. Danks L, et al. Elevated cytokine production restores bone resorption by human Btk-deficient osteoclasts. J Bone Miner Res. 2011;26(1):182-92.
20. Chang BY, et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther. 2011;13(4):R115.
21. Yoon SH, et al. Adenylate cyclase and calmodulin-dependent kinase have opposite effects on osteoclastogenesis by regulating the PKA-NFATc1 pathway. J Bone Miner Res. 2011;26(6):1217-29.
22. Bao X, et al. Acid sphingomyelinase regulates osteoclastogenesis by modulating sphingosine kinases downstream of RANKL signaling. Biochem Biophys Res Commun. 2011;405(4):533-7.
23. He Y, et al. Erk1 positively regulates osteoclast differentiation and bone resorptive activity. PLoS One. 2011;6(9):e24780.
24. Kukita A, et al. The transcription factor FBI-1/OCZF/LRF is expressed in osteoclasts and regulates RANKL-induced osteoclast formation in vitro and in vivo. Arthritis Rheum. 2011;63(9):2744-54.
25. Mahoney DJ, et al. TSG-6 inhibits osteoclast activity via an autocrine mechanism and is functionally synergistic with osteoprotegerin. Arthritis Rheum. 2011;63(4):1034-43.
26. Yasui T, et al. Epigenetic regulation of osteoclast differentiation: possible involvement of Jmjd3 in the histone demethylation of Nfatc1. J Bone Miner Res. 2011;26(11):2665-71.
27. Cantley MD, et al. Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro. J Cell Physiol. 2011;226(12):3233-41.
28. Kim JH, et al. RANKL induces NFATc1 acetylation and stability via histone acetyltransferases during osteoclast differentiation. Biochem J. 2011;436(2):253-62.
29. Hodge JM, et al. M-CSF potently augments RANKL-induced resorption activation in mature human osteoclasts. PLoS One. 2011;6(6):e21462.
30. Kimura K, et al. Anti-c-Fms antibody inhibits lipopolysaccharideinduced osteoclastogenesis in vivo. FEMS Immunol Med Microbiol. 2012;64(2):219-27.
31. Chen Z, et al. The critical role of IL-34 in osteoclastogenesis. PLoS One. 2011;6(4):e18689.
32. Chemel M, et al. Interleukin 34 expression is associated with synovitis severity in rheumatoid arthritis patients. Ann Rheum Dis. 2012;71(1):150-4.
33. Lee B, et al. Direct inhibition of human RANK+ osteoclast precursors identifies a homeostatic function of IL-1beta. J Immunol. 2010;185(10):5926-34.
34. Ignatius A, et al. Complement C3a and C5a modulate osteoclast formation and inflammatory response of osteoblasts in synergism with IL-1beta. J Cell Biochem. 2011;112(9):2594-605.
35. Lee GT, et al. Bone morphogenetic protein 6-induced interleukin-1beta expression in macrophages requires PU.1/Smad1 interaction. Mol Immunol. 2011;48(12-13):1540-7.
36. Schulze J, et al. Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells. J Bone Miner Res. 2011;26(4):704-17.
37. Saleh H, et al. Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro. Endocrinology. 2011;152 (5):1911-22.
38. Keller J, et al. Transgenic over-expression of interleukin-33 in osteoblasts results in decreased osteoclastogenesis. Biochem Biophys Res Commun. 2012;417(1):217-22.
39. Zaiss MM, et al. IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-alpha-mediated bone loss. J Immunol. 2011;186 (11):6097-105.
40. Funakoshi-Tago M, et al. JAK2 is an important signal transducer in IL-33-induced NF-kappaB activation. Cell Signal. 2011;23(2):363-70.
41. Ali S, et al. The dual function cytokine IL-33 interacts with the transcription factor NF-kappaB to dampen NF-kappaB-stimulated gene transcription. J Immunol. 2011;187(4):1609-16.
42. Saidi S, et al. IL-33 is expressed in human osteoblasts, but has no direct effect on bone remodeling. Cytokine. 2011;53(3):347-54.
43. Kageyama Y, et al. Involvement of IL-33 in the pathogenesis of rheumatoid arthritis: the effect of etanercept on the serum levels of IL-33. Mod Rheumatol. 2012;22(1):89-93.
44. Hong YS, et al. Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis. J Korean Med Sci. 2011;26(9):1132-9.
45. Talabot-Ayer D, et al. Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine. 2012;79(1):32-7.
46. Nagano K et al. The tumor necrosis factor type 2 receptor plays a protective role in tumor necrosis factor-alpha-induced bone resorption lacunae on mouse calvariae. J Bone Miner Metab. 2011;29(6):671-81.
47. Atanga E, et al. TNFalpha inhibits the development of osteoclasts through osteoblast-derived GM-CSF. Bone. 2011;49(5):1090-100.
48. Goto H, et al. Primary human bone marrow adipocytes support TNF-alpha-induced osteoclast differentiation and function through RANKL expression. Cytokine. 2011;56(3):662-8.
49. Yarilina A, et al. TNF activates calcium-nuclear factor of activated T cells (NFAT)c1 signaling pathways in human macrophages. Proc Natl Acad Sci USA. 2011;108(4):1573-8.
50. Finzel S, et al. Repair of bone erosions in rheumatoid arthritis treated with tumour necrosis factor inhibitors is based on bone apposition at the base of the erosion. Ann Rheum Dis. 2011;70(9):1587-93.
51. Huang H, et al. Dose-specific effects of tumor necrosis factor alpha on osteogenic differentiation of mesenchymal stem cells. Cell Prolif 2011;44(5):420-7.
52. Tsukasaki M, et al. Expression of POEM, a positive regulator of osteoblast differentiation, is suppressed by TNF-alpha. Biochem Biophys Res Commun. 2011;410(4):766-70.
53. Suzuki M, et al. Intercellular adhesion molecule-1 on synovial cells attenuated interleukin-6-induced inhibition of osteoclastogenesis induced by receptor activator for nuclear factor kappaB ligand. Clin Exp Immunol. 2011;163(1):88-95.
54. Cheung WY, Simmons CA, You L. Osteocyte apoptosis regulates osteoclast precursor adhesion via osteocytic IL-6 secretion and endothelial ICAM-1 expression. Bone. 2012;50(1):104-10.
55. Honda K. Interleukin-6 and soluble interleukin-6 receptor suppress osteoclastic differentiation by inducing PGE(2) production in chondrocytes. J Oral Sci. 2011;53(1):87-96.
56. Terpos E, et al. Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. Clin Exp Rheumatol. 2011;29(6):921-5.
57. Kanbe K, et al. Osteoprotegerin expression in bone marrow by treatment with tocilizumab in rheumatoid arthritis. Rheumatol Int. 2011;Jul 26.
58. Natsume H, et al. Wnt3a regulates tumor necrosis factor-alpha-stimulated interleukin-6 release in osteoblasts. Mol Cell Endocrinol. 2011;331(1):66-72.
59. Kato K, et al. AMP-activated protein kinase regulates PDGF-BB-stimulated interleukin-6 synthesis in osteoblasts: Involvement of mitogen-activated protein kinases. Life Sci. 2012;90(1-2):71-6.
60. Guo L, et al. Angiotensin II induces interleukin-6 synthesis in osteoblasts through ERK1/2 pathway via AT1 receptor. Arch Oral Biol. 2011;56(3):205-11.
61. Rego D, et al. IL-6 production is positively regulated by two distinct Src homology domain 2-containing tyrosine phosphatase-1 (SHP-1)-dependent CCAAT/enhancer-binding protein beta and NF-kappaB pathways and an SHP-1-independent NF-kappaB pathway in lipopolysaccharide-stimulated bone marrow-derived macrophages. J Immunol. 2011;186(9):5443-56.
62. Kamiya S, et al. IL-27 suppresses RANKL expression in CD4+ T cells in part through STAT3. Immunol Lett. 2011;138(1):47-53.
63. Halvorsen EH, et al. Interleukin-15 induces interleukin-17 production by synovial T cell lines from patients with rheumatoid arthritis. Scand J Immunol. 2011;73(3):243-9.
64. Hueber AJ, et al. Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol. 2010;184(7):3336-40.
65. Pollinger B, et al. Th17 cells, not IL-17+ gammadelta T cells, drive arthritic bone destruction in mice and humans. J Immunol. 2011;186(4):2602-12.
66. Abdollahi-Roodsaz S, et al. Destructive role of myeloid differentiation factor 88 and protective role of TIR-containing adaptor inducing interferon beta in IL-17-dependent arthritis. Arthritis Rheum. 2011, Dec 6.
67. Oostlander AE, et al. T cell-mediated increased osteoclast formation from peripheral blood as a mechanism for Crohn's disease-associated bone loss. J Cell Biochem. 2012;113(1):260-8.
68. Park YE, et al. IL-17 increases cadherin-11 expression in a model of autoimmune experimental arthritis and in rheumatoid arthritis. Immunol Lett. 2011;140(1-2):97-103.
69. Zhang F, et al. Interleukin-17A induces cathepsin K and MMP-9 expression in osteoclasts via celecoxib-blocked prostaglandin E2 in osteoblasts. Biochimie. 2011;93(2):296-305.
70. Zwerina K, et al. Anti IL-17A therapy inhibits bone loss in TNF-alpha-mediated murine arthritis by modulation of the T-cell balance. Eur J Immunol. 2012;42(2):413-23.
71. Sadik CD, et al. IL-17RA signaling amplifies antibody-induced arthritis. PLoS One. 2011;6(10):e26342.
72. Pickens SR, et al. Anti-CXCL5 therapy ameliorates IL-17-induced arthritis by decreasing joint vascularization. Angiogenesis. 2011;14 (4):443-55.
73. Rampersad RR, et al. Enhanced Th17-cell responses render CCR2-deficient mice more susceptible for autoimmune arthritis. PLoS One. 2011;6(10):e25833.
74. Kaiwen W, et al. Changes and significance of IL-25 in chicken collagen II-induced experimental arthritis (CIA). Rheumatol Int. 2011;May 29.
75. Yu M, et al. NF-kappaB signaling participates in both RANKL-and IL-4-induced macrophage fusion: receptor cross-talk leads to alterations in NF-kappaB pathways. J Immunol. 2011;187(4):1797-806.
76. Cheng J, et al. Interleukin-4 inhibits RANKL-induced NFATc1 expression via STAT6: a novel mechanism mediating its blockade of osteoclastogenesis. J Cell Biochem. 2011;112(11):3385-92.
77. Ma HM, Wu Z, Nakanishi H. Phosphatidylserine-containing liposomes suppress inflammatory bone loss by ameliorating the cytokine imbalance provoked by infiltrated macrophages. Lab Invest. 2011;91(6):921-31.
78. Kohara H, et al. IFN-gamma directly inhibits TNF-alpha-induced osteoclastogenesis in vitro and in vivo and induces apoptosis mediated by Fas/Fas ligand interactions. Immunol Lett. 2011;137 (1-2):53-61.
79. Ayon Haro ER, et al. Locally administered interferon-gamma accelerates lipopolysaccharide-induced osteoclastogenesis independent of immunohistological RANKL upregulation. J Periodontal Res. 2011;46(3):361-73.
80. Cheng J, et al. Molecular mechanisms of the biphasic effects of interferon-gamma on osteoclastogenesis. J Interferon Cytokine Res. 2012;32(1):34-45.
81. Yasui T, et al. Regulation of RANKL-induced osteoclastogenesis by TGF-beta through molecular interaction between Smad3 and Traf6. J Bone Miner Res. 2011;26(7):1447-56.
82. Park MK, et al. IL-15 promotes osteoclastogenesis via the PLD pathway in rheumatoid arthritis. Immunol Lett. 2011;139(1-2):42-51.
83. Kim YG, et al. The influence of interleukin-32gamma on osteoclastogenesis with a focus on fusion-related genes. J Clin Immunol. 2012;32(1):201-6.
84. Pickens SR, et al. Local expression of interleukin-27 ameliorates collagen-induced arthritis. Arthritis Rheum. 2011;63(8):2289-98.
85. Hsu YH, Hsieh PP, Chang MS. Interleukin-19 blockade attenuates collagen-induced arthritis in rats. Rheumatology (Oxford). 2012;51 (3):434-42.
86. Hsu YH, Chang MS. Interleukin-20 antibody is a potential therapeutic agent for experimental arthritis. Arthritis Rheum. 2010;62 (11):3311-21.
87. Hsu YH, et al. Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss. J Exp Med. 2011;208(9):1849-61.
88. Kwok SK, et al. Interleukin-21 promotes osteoclastogenesis in rheumatoid arthritis in humans and mice. Arthritis Rheum. 2012;64(3):p740-51.
89. Marijnissen RJ, et al. Increased expression of interleukin-22 by synovial Th17 cells during late stages of murine experimental arthritis is controlled by interleukin-1 and enhances bone degradation. Arthritis Rheum. 2011;63(10):2939-48.
90. Kim KW, et al. IL-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts. Arthritis Rheum. 2011;Oct 27.
91. Guma M, et al. JNK1 controls mast cell degranulation and IL-1 {beta} production in inflammatory arthritis. Proc Natl Acad Sci USA. 2010;107(51):22122-7.
92. Polzer K, et al. Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis. Arthritis Rheum. 2011;63(3):670-80.
93. Zwerina K, et al. Vitamin D receptor regulates TNF-mediated arthritis. Ann Rheum Dis. 2011;70(6):1122-9.
94. Bluml S, et al. Essential role of microRNA-155 in the pathogenesis of autoimmune arthritis in mice. Arthritis Rheum. 2011;63(5):1281-8.
95. Sugatani T, Vacher J, Hruska KA. A microRNA expression signature of osteoclastogenesis. Blood. 2011;117(13):3648-57.
96. Nakasa T, et al. The inhibitory effect of microRNA-146a expression on bone destruction in collagen-induced arthritis. Arthritis Rheum. 2011;63(6):1582-90.